Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
The Graph (GRT) Retesting Bullish Breakout Pattern – Is a Rebound Next?

The Graph (GRT) Retesting Bullish Breakout Pattern – Is a Rebound Next?

CoinsProbeCoinsProbe2025/05/19 01:55
By:Nilesh Hembade

Date: Sat, May 17, 2025 | 05:58 PM GMT

The cryptocurrency market has mounted a solid comeback in recent weeks, with Ethereum (ETH) continuing to lead the charge. ETH has surged more than 53% in the past month and is now trading below $2,500 after hitting a high of $2,700 — a level not seen since early January. This renewed bullish momentum is lifting sentiment across altcoins , including The Graph (GRT).

GRT has recorded strong monthly gains of over 35%, although it’s slightly down on the day by around 5%. But instead of causing concern, this pullback is turning heads. The token is now retesting a critical breakout level — one that could act as a launchpad for its next move.

The Graph (GRT) Retesting Bullish Breakout Pattern – Is a Rebound Next? image 0 Source: Coinmarketcap

Retesting Inverse Head and Shoulders Breakout

A closer look at the daily chart reveals a textbook inverse head and shoulders pattern — a powerful bullish reversal formation. This pattern typically indicates that a downtrend has bottomed out and a new uptrend is potentially starting.

GRT confirmed this bullish pattern earlier this month. The token bounced from the right shoulder near $0.086 and broke out above the neckline resistance at $0.1070. That breakout took the price up to a local high of $0.1311.

The Graph (GRT) Retesting Bullish Breakout Pattern – Is a Rebound Next? image 1 The Graph (GRT) Daily Chart/Coinsprobe (Source: Tradingview)

However, GRT couldn’t maintain that momentum and has since corrected over 15%. Now, the price is revisiting the $0.10 zone — which previously acted as resistance and is now being tested as support. Coincidentally, this level aligns with the 100-day moving average (100 MA), adding further significance to the area.

What’s Next for GRT?

The $0.10 zone is now a critical pivot. If GRT can hold this support and bounce, it would validate the inverse head and shoulders breakout and suggest further upside.

  • If support holds: The next bullish target lies around $0.1472 — a 40% potential upside from current levels.
  • If support fails: A breakdown below $0.10 could invalidate the bullish structure, potentially leading to further downside.

Much will depend on broader crypto sentiment. If Ethereum continues its rally and altcoins stay strong, GRT could follow suit with a renewed push higher from this retest zone.

Disclaimer: This article is for informational purposes only and not financial advice. Always do your own research before making investment decisions.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Citrini, once the most prominent bull in AI hardware, has now significantly reduced his semiconductor holdings and currently holds some short positions. He believes that the financing structure for AI infrastructure has shifted from tech giants' own cash flows to equity and debt markets, and that sentiment alone could sever the funding chain and impact fundamentals. Strategically, he is long Meta and short Google. Citrini also asserts that the bottleneck in AI pharmaceutical development is not computational power, but rather a "lack of monkeys."

华尔街见闻•2026/10/26 03:36
Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business

Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.

智通财经•2026/10/26 03:11

Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital

As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.

智通财经•2026/10/26 02:43